Drugs in development for the treatment of multiple sclerosis: Antigen-specific therapies

Expert Opinion on Investigational Drugs

Volumn 5, Issue 10, 1996, Pages 1331-1348

  Spack, E G ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

altered peptide ligand; anergy; antigen specific therapy; apoptosis; bystander suppression; multiple sclerosis

Indexed keywords

AUTOANTIGEN; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE DERIVATIVE; T LYMPHOCYTE RECEPTOR; VACCINE;

ANERGY; ANIMAL MODEL; ANTIGEN SPECIFICITY; APOPTOSIS; AUTOIMMUNITY; CLINICAL TRIAL; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; REVIEW; T LYMPHOCYTE; VACCINATION;

EID: 0029803896     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.5.10.1331     Document Type: Review

References (0)